| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mahmut Selçu. Safe and Effective Use of Low-Dose Clozapine for Tardive Dyskinesia in a Patient with Schizophrenia and Comorbid Epilepsy: A Case Report. Psychiatry and clinical psychopharmacology. vol 33. issue 2. 2024-05-21. PMID:38765926. |
safe and effective use of low-dose clozapine for tardive dyskinesia in a patient with schizophrenia and comorbid epilepsy: a case report. |
2024-05-21 |
2024-05-27 |
Not clear |
| Mahmut Selçu. Safe and Effective Use of Low-Dose Clozapine for Tardive Dyskinesia in a Patient with Schizophrenia and Comorbid Epilepsy: A Case Report. Psychiatry and clinical psychopharmacology. vol 33. issue 2. 2024-05-21. PMID:38765926. |
atypical antipsychotic clozapine has a special therapeutic impact on tardive dyskinesia and treatment-resistant schizophrenia. |
2024-05-21 |
2024-05-27 |
Not clear |
| Mahmut Selçu. Safe and Effective Use of Low-Dose Clozapine for Tardive Dyskinesia in a Patient with Schizophrenia and Comorbid Epilepsy: A Case Report. Psychiatry and clinical psychopharmacology. vol 33. issue 2. 2024-05-21. PMID:38765926. |
for this reason, most clinicians avoid using clozapine in patients with schizophrenia and epilepsy. |
2024-05-21 |
2024-05-27 |
Not clear |
| Delaney R Brainerd, Bruce Alexander, Marshall J Tague, Brian C Lun. Association Between Clozapine Exposure and Risk of Hematologic Malignancies in Veterans With Schizophrenia. The Journal of clinical psychiatry. vol 85. issue 2. 2024-05-20. PMID:38767931. |
association between clozapine exposure and risk of hematologic malignancies in veterans with schizophrenia. |
2024-05-20 |
2024-05-27 |
Not clear |
| Nadia El Ouni Amami, Husen Ali-Diabacte, Sarra Ateb, Hamadi Ben Rejeb, Avicenne Bellis, Reza Bellis, Dominique Januel, Noomane Bouazi. Clozapine-induced cholinergic urticaria: a case report. Therapeutic advances in psychopharmacology. vol 14. 2024-05-16. PMID:38745850. |
we present the first reported case of cholinergic urticaria induced by clozapine, in a 25-year-old male with treatment-resistant schizophrenia. |
2024-05-16 |
2024-05-27 |
Not clear |
| Florine M Wiss, Samuel S Allemann, Henriette E Meyer Zu Schwabedissen, Céline K Stäuble, Thorsten Mikoteit, Markus L Lamper. Recurrent high creatine kinase levels under clozapine treatment - a case report assessing a suspected adverse drug reaction. Frontiers in psychiatry. vol 15. 2024-05-14. PMID:38742124. |
a 36-year-old male patient with catatonic schizophrenia was treated with clozapine. |
2024-05-14 |
2024-05-27 |
Not clear |
| Kyle Hewitt, Xu-Feng Huan. Comment on "Impact of clozapine on the expression of miR-675-3p in plasma exosomes derived from patients with schizophrenia". The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2024-05-02. PMID:38693660. |
comment on "impact of clozapine on the expression of mir-675-3p in plasma exosomes derived from patients with schizophrenia". |
2024-05-02 |
2024-05-04 |
Not clear |
| Brooke Gessner, Michelle Carter, Kiana Rahnama, Alberto Almeida, Colleen Borralho, Tamara Mihic, Joan C Y Ng, Joseph H Puyat, Angela Russolillo, Katelyn C Halpap. Clozapine clinical toolkit optimizes inpatient clozapine monitoring. The mental health clinician. vol 14. issue 2. 2024-05-02. PMID:38694883. |
clozapine is the most effective antipsychotic in the management of treatment-resistant schizophrenia; however, its use is challenging due to the risk of severe adverse effects. |
2024-05-02 |
2024-05-04 |
Not clear |
| Yun Tien, Xi-Yu Wang, Shang-Chien Huang, Hsiang-Ping Huan. Beneficial Effects of Concomitant Long-Acting Injectable Antipsychotics on Time to Rehospitalization in Patients With Treatment-Resistant Schizophrenia Receiving Clozapine: A Retrospective Cohort Study. The Journal of clinical psychiatry. vol 85. issue 2. 2024-05-02. PMID:38696112. |
beneficial effects of concomitant long-acting injectable antipsychotics on time to rehospitalization in patients with treatment-resistant schizophrenia receiving clozapine: a retrospective cohort study. |
2024-05-02 |
2024-05-04 |
Not clear |
| Jose M Rubio, John M Kane, Antti Tanskanen, Jari Tiihonen, Heidi Taipal. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland. The lancet. Psychiatry. 2024-05-02. PMID:38697177. |
agranulocytosis is a life-threatening side-effect of clozapine, the only approved drug for treatment-resistant schizophrenia. |
2024-05-02 |
2024-05-05 |
Not clear |
| Ofer Agid, Benedicto Crespo-Facorro, Andrea de Bartolomeis, Andrea Fagiolini, Oliver D Howes, Niko Seppälä, Christoph U Correl. Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 84. 2024-04-24. PMID:38657339. |
overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice. |
2024-04-24 |
2024-04-28 |
Not clear |
| Ofer Agid, Benedicto Crespo-Facorro, Andrea de Bartolomeis, Andrea Fagiolini, Oliver D Howes, Niko Seppälä, Christoph U Correl. Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 84. 2024-04-24. PMID:38657339. |
clozapine is the only approved antipsychotic for treatment-resistant schizophrenia (trs). |
2024-04-24 |
2024-04-28 |
Not clear |
| Emilio Fernandez-Egea, Shanquan Chen, Estela Sangüesa, Patricia Gassó, Marjan Biria, James Plaistow, Isaac Jarratt-Barnham, Nuria Segarra, Sergi Mas, Maria-Pilar Ribate, Cristina B García, Naomi A Fineberg, Yulia Worbe, Rudolf N Cardinal, Trevor W Robbin. The role of psychosis and clozapine load in excessive checking in treatment-resistant schizophrenia: longitudinal observational study. The British journal of psychiatry : the journal of mental science. vol 224. issue 5. 2024-04-23. PMID:38652060. |
the role of psychosis and clozapine load in excessive checking in treatment-resistant schizophrenia: longitudinal observational study. |
2024-04-23 |
2024-04-26 |
Not clear |
| Shimeng Jiao, Nana Li, Ting Cao, Liwei Wang, Hui Chen, Chenquan Lin, Hualin Ca. Differential impact of intermittent versus continuous treatment with clozapine on fatty acid metabolism in the brain of an MK-801-induced mouse model of schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2024-04-20. PMID:38642730. |
differential impact of intermittent versus continuous treatment with clozapine on fatty acid metabolism in the brain of an mk-801-induced mouse model of schizophrenia. |
2024-04-20 |
2024-04-23 |
mouse |
| Shimeng Jiao, Nana Li, Ting Cao, Liwei Wang, Hui Chen, Chenquan Lin, Hualin Ca. Differential impact of intermittent versus continuous treatment with clozapine on fatty acid metabolism in the brain of an MK-801-induced mouse model of schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2024-04-20. PMID:38642730. |
we thus utilized an mk-801-induced animal model of schizophrenia to evaluate whether two treatment strategies of clozapine would affect drug response and fa metabolism differently in the brain. |
2024-04-20 |
2024-04-23 |
mouse |
| Xiding Yang, Qiangyong Yan, Lingfeng Yang, Jingjing Li, Xiao Fan, Jindong Chen, Haishan Wu, Yongyu Yang, Ronghua Zhu, Pingfei Fan. Effect of propranolol on pharmacokinetics of clozapine in schizophrenic patients: a meta-analysis. European journal of clinical pharmacology. 2024-04-19. PMID:38639762. |
clozapine is the effective therapy for treatment-refractory schizophrenia. |
2024-04-19 |
2024-04-21 |
Not clear |
| Kohei Kitagawa, Shusuke Uekusa, Yuki Hanai, Itsuki Kimura, Masaru Tsukahara, Azusa Kagawa, Kenji Sasaoka, Yui Sakishiro, Ayaka Miyake, Yuki Watanabe, Daiki Baba, Masafumi Kodama, Yoshiki Kishi, Norihito Yamada, Takashi Yoshio, Kazuhiro Matsu. Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: A 12-year prescription survey pre- and post-introduction of clozapine. Asian journal of psychiatry. vol 96. 2024-04-19. PMID:38640549. |
changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in japan: a 12-year prescription survey pre- and post-introduction of clozapine. |
2024-04-19 |
2024-04-22 |
Not clear |
| Kohei Kitagawa, Shusuke Uekusa, Yuki Hanai, Itsuki Kimura, Masaru Tsukahara, Azusa Kagawa, Kenji Sasaoka, Yui Sakishiro, Ayaka Miyake, Yuki Watanabe, Daiki Baba, Masafumi Kodama, Yoshiki Kishi, Norihito Yamada, Takashi Yoshio, Kazuhiro Matsu. Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: A 12-year prescription survey pre- and post-introduction of clozapine. Asian journal of psychiatry. vol 96. 2024-04-19. PMID:38640549. |
we aimed to investigate the changes in psychopharmacotherapy in patients with schizophrenia over 12 years pre- and post-introduction of clozapine to clarify how psychopharmacotherapy for patients with schizophrenia has changed with the introduction of clozapine. |
2024-04-19 |
2024-04-22 |
Not clear |
| Kohei Kitagawa, Shusuke Uekusa, Yuki Hanai, Itsuki Kimura, Masaru Tsukahara, Azusa Kagawa, Kenji Sasaoka, Yui Sakishiro, Ayaka Miyake, Yuki Watanabe, Daiki Baba, Masafumi Kodama, Yoshiki Kishi, Norihito Yamada, Takashi Yoshio, Kazuhiro Matsu. Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: A 12-year prescription survey pre- and post-introduction of clozapine. Asian journal of psychiatry. vol 96. 2024-04-19. PMID:38640549. |
the increase in clozapine prescription has contributed to an increased rate of antipsychotic monotherapy and a decreased rate of polypharmacy, promoting the optimization of schizophrenia medication. |
2024-04-19 |
2024-04-22 |
Not clear |
| Kohei Kitagawa, Shusuke Uekusa, Yuki Hanai, Itsuki Kimura, Masaru Tsukahara, Azusa Kagawa, Kenji Sasaoka, Yui Sakishiro, Ayaka Miyake, Yuki Watanabe, Daiki Baba, Masafumi Kodama, Yoshiki Kishi, Norihito Yamada, Takashi Yoshio, Kazuhiro Matsu. Changes in psychopharmacotherapy for patients with schizophrenia in a psychiatric institution in Japan: A 12-year prescription survey pre- and post-introduction of clozapine. Asian journal of psychiatry. vol 96. 2024-04-19. PMID:38640549. |
clozapine therapy should be further promoted in japan to reduce treatment-resistant schizophrenia due to polypharmacy as much as possible. |
2024-04-19 |
2024-04-22 |
Not clear |